Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRF1 | P14222 | 15/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2054407 | 0.89 | PRF1 (0.53) | PRF1CYP3A4LMNAMAPTGAA | |
| SCHEMBL21508370 | 0.84 | PRF1 (0.56) | PRF1LMNAMAPTGAAALDH1A1 | |
| SCHEMBL14761557 | 0.80 | PRF1 (0.50) | PRF1CYP3A4LMNAMAPTGAA | |
| SCHEMBL2021232 | 0.80 | PRF1 (0.47) | PRF1CYP3A4LMNAMAPTGAA | |
| SCHEMBL18713961 | 0.80 | PRF1 (0.52) | PRF1LMNAMAPTGAAALDH1A1 | |
| SCHEMBL14761558 | 0.79 | PRF1 (0.50) | PRF1CYP3A4LMNAMAPTGAA | |
| SCHEMBL16573996 | 0.79 | PRF1 (0.61) | PRF1LMNAMAPTGAAALDH1A1 | |
| SCHEMBL2052151 | 0.78 | PRF1 (0.49) | PRF1CYP3A4LMNAMAPTGAA | |
| SCHEMBL13469961 | 0.78 | PRF1 (0.65) | PRF1LMNAMAPTGAAACHE | |
| SCHEMBL14761567 | 0.77 | PRF1 (0.50) | PRF1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130065897-A1 | COMPOUNDS, PREPARATION AND USES THEREOF | PETER MACCALLUM CANCER INSTITUTE (AU) | 2013-03-14 | — | — | US | disclosed |
| EP-2515903-A1 | COMPOUNDS, PREPARATIONS AND USES THEREOF | Peter MacCallum Cancer Institute (AU) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011075784-A1 | COMPOUNDS, PREPARATIONS AND USES THEREOF | PETER MACCALLUM CANCER INSTITUTE (AU) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065897-A1 | COMPOUNDS, PREPARATION AND USES THEREOF | PRF1, GZMB, SERPINB1 | PRF1 1/4885CYP3A4 2225/4885LMNA 715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.